We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Epistem | LSE:EHP | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 85.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
02/8/2016 13:54 | Trading update. Monitoring the progress closely. | the ghost who walks | |
29/7/2016 08:30 | https://genedrive.co | the ghost who walks | |
29/7/2016 08:21 | Wondering if the new website will have upgraded investor relations disclosures. Closely watching. | the ghost who walks | |
29/7/2016 07:05 | We need a progress update. Look at the Cepheid Genexperts site - so much information and news flow about their own Tb/RIF assay. Their system is larger and more expensive than GDRs, but they appear to already occupy the same market in India market that GDR are trying to get into. I expected the new CEO to have made more positive noises by now. To make my position clear, I am not invested now, having lost money during Mathew Walls disastrous era, however I still like the overall concept and package hence would pile in again if the problems I believe have existed are now resolved. | azzi | |
29/7/2016 06:16 | New website also? Monitoring. | the ghost who walks | |
27/7/2016 13:44 | Mgt bought shares. Monitoring closely | the ghost who walks | |
27/7/2016 13:43 | Looking forward to the next update. Name change interesting | the ghost who walks | |
26/7/2016 06:50 | A progress update would be nice on the take up go the Tb assay in zinnia. Also, more details on the HCV assay, when is this planned to be launched and where? | azzi | |
25/7/2016 09:25 | Name change... Watching with interest | the ghost who walks | |
07/7/2016 20:59 | They must be getting closer to releasing a progress update on the uptake of the Tb test in India. Very little news flow since the new CEO took over, who knows where this company will go. Sorry, my post is of no real help at all, just releasing some frustration. | azzi | |
05/5/2016 19:06 | Very interesting. Watching closely. | the ghost who walks | |
04/5/2016 18:39 | Ok - some positive news flow at last. As I understand, every assay developed needs successful chemistry, of course, however I have been more worried about the gene drive device itself, I think this is where the problems are or have been. Let's hope it's the latter. Watching closely. | azzi | |
04/5/2016 18:39 | Ok - some positive news flow at last. As I understand, every assay developed needs successful chemistry, of course, however I have been more worried about the gene drive device itself, I think this is where the problems are or have been. Let's hope it's the latter. Watching closely. | azzi | |
04/5/2016 18:39 | Ok - some positive news flow at last. As I understand, every assay developed needs successful chemistry, of course, however I have been more worried about the gene drive device itself, I think this is where the problems are or have been. Let's hope it's the latter. Watching closely. | azzi | |
04/5/2016 07:26 | Video interview with David Budd David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says recent tests show its rapid diagnostic system Genedrive is “as accurate as the gold standard”. Genedrive, which has already launched in India for TB, performed well in EU-funded hepatitis (HCV) study carried out by Institut Pasteur and Hopital Cochin in Paris. It was 100% accurate in detecting inherited genetic polymorphisms in Hepatitis (HCV) patients compared to the current 'gold-standard' laboratory test, Roche's TaqMan PCR. “We feel that based on the results that we’ve had today with Institut Pasteur on the qualitative side of detecting HCV that we are in a great position now to go out and find partners that will work with us on commercialising and taking that product to market,” Budd says. | proactivest | |
18/4/2016 14:53 | Video interview with David Budd David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says the news it has reached a major milestone in its development with the full commercial launch of its Genedrive tuberculosis (TB) and antibiotic resistance test, is “hugely significant”. The company, a specialist in molecular diagnostics and personalised medicine, has teamed up with Xcelris Labs to start selling the product in India. Next up, Budd says, the company hopes to build up a “menu of tests” over time, now that the company has a “robust technology platform in place”. | proactivest | |
18/4/2016 07:00 | This is good | the ghost who walks | |
31/3/2016 07:57 | More smoke and mirror`s!! So the Indian Tb launch has been delayed! ..."and the delay in developing sales of Genedrive(R) and associated TB tests in India". They are only now embarking on "launch training" with their distribution partner - what the hell of they been doing for the last three years? I remain concerned that there are still problems with the Genedrive technology, they are claiming validation in some testing centers, however this is a bare minimum requirement for any technology and does not prove they are ready to scale up to meet the market needs. The Indian Tb market will be hard to break into, meaningful sales may be years away. I can`t get a feel for their strategy for their hepatitis C assay, this seems to still be at the development phase. Ads for "IL28" - I can`t find out what on earth this is for! Can someone enlighten me? Share placing coming up and clear concerns about future funding have once again put me off investing. I will continue to watch this disaster unfold. Very sad! Azzi | azzi | |
21/3/2016 08:36 | I`m watching for evidence that it might be worth me re-investing again. However with the lack of information against the backdrop of a falling sp, I remain worried that more delays are taking place. The big question to me is what is the cause of the delays. I have been expecting a positive update on the Indian Tb strategy, but I can`t find anything at all. I wonder what the new CEO is uncovering? | azzi | |
20/3/2016 20:31 | What's your expectation Azzi? | the ghost who walks | |
09/3/2016 15:19 | I wonder what delays they are going to announce next......? | azzi | |
19/2/2016 15:04 | Actually earlier than anticipated. Great | the ghost who walks | |
19/2/2016 08:54 | Ceo start date confirmed. | the ghost who walks |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions